Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
141-160 of 1,743 trials

B-cell Acute Lymphoblastic Leukemia: UCART22 Treatment Study

We are testing a new engineered T-cell therapy, UCART22, for patients with relapsed or refractory B-ALL. The study aims to evaluate its safety and effectiveness, especially for those who have not responded to other therapies.

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Cancer Treatment: HRO761 for Specific Genetic Changes

We are studying the effects of HRO761 in cancer patients with certain DNA alterations known as Microsatellite Instability-High or Mismatch Repair Deficiency. This trial will help us understand how well this treatment works alone and with other therapies.

Microsatellite Instability (MSI) and Mismatch Repair Cancer Syndrome>2 yearsSafety phase (I)Oncology

Advanced Hepatobiliary Cancer: New Immunomodulators

We are studying new immunomodulators to see if they can improve treatment outcomes for patients with advanced hepatobiliary cancer. This includes testing their safety and effectiveness alone and with other cancer therapies.

Bile Duct CancerGallbladder CancerHepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology

Tuberous Sclerosis Complex: mTOR Inhibitor Treatment in Infants

We are studying the effects of a new treatment on brain development in infants with tuberous sclerosis complex. This trial aims to see if the treatment improves cognitive and behavioral outcomes compared to standard care.

Tuberous Sclerosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Breast Cancer Treatment: Tucatinib and Capecitabine

We are studying a combination of tucatinib, capecitabine, and trastuzumab for patients with HER2-positive breast cancer that has spread to the meninges. The goal is to see if this treatment improves survival and quality of life.

HER2-Amplified Metastatic Breast Cancer with Leptomeningeal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Small Cell Lung Cancer: Trilaciclib vs Placebo

We are studying whether trilaciclib can improve survival for patients with extensive stage small cell lung cancer receiving chemotherapy. The trial will also assess its effects on tumor response and safety compared to a placebo.

Extensive Stage Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Triple Negative Metastatic Breast Cancer: Sacituzumab Govitecan Study

We are investigating the safety and effectiveness of a new treatment for patients with triple negative metastatic breast cancer whose disease has worsened after prior therapies. This study will help us learn more about how well this treatment works and its safety profile.

Triple Negative Metastatic Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Prostate Cancer: New Treatment Approach with Hormone Therapy

We are studying whether adding short-term hormone therapy to a targeted treatment helps men with recurrent prostate cancer and a limited number of metastases live longer and improve their quality of life.

Oligorecurrent Hormone-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncologyUrology

Pancreatic Cancer: New Treatment Combination Study

We are studying a new treatment combining autogene cevumeran, atezolizumab, and mFOLFIRINOX for patients with resected pancreatic ductal adenocarcinoma. The goal is to see if this combination improves survival compared to standard mFOLFIRINOX alone.

Pancreatic Cancer>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessCost ReimbursementOncology

CAR-T-Cell Treatment for High-Risk Mantle Cell Lymphoma

We are exploring a new CAR-T-cell therapy for patients with untreated high-risk Mantle Cell Lymphoma. The study compares this new approach to the standard treatment to see which is more effective and safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Advanced Colorectal Cancer: Cetuximab with Encorafenib and Binimetinib

We are studying a combination of three medications for patients with BRAF V600E mutated advanced colorectal cancer. The goal is to see if this treatment can help make surgery possible and improve overall health outcomes.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Eplontersen for Transthyretin-Mediated Amyloid Cardiomyopathy

We are studying the long-term safety of eplontersen in adults with ATTR-CM. This trial will help us understand how well the treatment is tolerated over an extended period.

Transthyretin-Mediated Amyloid Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Cutaneous T-Cell Lymphoma: Mogamulizumab and Skin Radiation Therapy

We are studying a new treatment combining an antibody and skin radiation for patients with stage IB-IIB cutaneous T-cell lymphoma. The goal is to see if this approach improves survival and response rates compared to standard treatments.

Cutaneous T-cell LymphomaMycosis Fungoides and Sézary Syndrome>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Cardiovascular Safety: BI 456906 for Overweight Individuals

We are testing a new medication for people with overweight or obesity and cardiovascular disease to see if it is as safe as a placebo. The study will also look at its effects on blood pressure and waist size.

Obesity>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Advanced Solid Tumors: INCA033890 Study

We are testing a new treatment called INCA033890 for individuals with advanced or metastatic solid tumors. This study aims to understand its safety and how it can be used in future treatments.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Advanced Breast Cancer: [177Lu]Lu-NeoB with Ribociclib and Fulvestrant

We are exploring a new treatment combination for patients with ER+, HER2-, and GRPR+ advanced breast cancer who have not responded to earlier therapies. The study aims to assess the safety and effectiveness of this approach.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)EndocrinologyOncology

Methylmalonic Acidemia: mRNA-3705 Treatment Study

We are testing a new treatment, mRNA-3705, for individuals with isolated Methylmalonic Acidemia. The study aims to evaluate its safety and how well it lowers harmful acid levels in the blood.

Methylmalonic Aciduria>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Beta-Thalassemia: Luspatercept for Children

We are studying a new treatment called luspatercept for children with beta-thalassemia to find a safe dose and evaluate its effects on blood health. This trial includes both transfusion-dependent and non-transfusion-dependent participants.

Beta Thalassemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Atrial Fibrillation: Warfarin Study for Dialysis Patients

We are investigating the safety and effectiveness of warfarin in patients with atrial fibrillation who are on dialysis. This study aims to understand how this medication impacts their health.

Atrial FibrillationEnd-Stage Renal Disease>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyNephrology

Myelofibrosis and Essential Thrombocythemia: INCA033989 Study

We are evaluating the effects and safety of a new treatment called INCA033989 for individuals with myelofibrosis or essential thrombocythemia. This study aims to understand how well it works compared to current options.

Myeloproliferative Neoplasms>2 yearsSafety phase (I)HematologyOncology